The present invention relates to a peptide consisting of a sequence of 5 to 30, preferably 6 to 12, most preferably 10 to 12 amino acids, wherein (a) at least 2/3 of said amino acids have a functional group or side chain which is negatively charged at neutral pH; (b) amino acids which do not have a functional group or side chain which is negatively charged at neutral pH, if present, meet one or both of requirements (i) and (ii): (i) none of them has a functional group or side chain which is positively charged at neutral pH; and (ii) at least one of them has a side chain which does not bear a net charge at neutral pH or which has a functional group or side chain that does not bear a net charge at neutral pH.
Anti-apoc3 antibodies and methods of use thereof
Dasilva-Jardine, Paul; Haard, Hans De; Landro, James A.
Jan 2018
Marker Sequences for Diagnosing and Stratifying Systemic Sclerosis Patients
The invention relates to a method for identifying markers for systemic sclerosis (scleroderma, SSc) and to the markers identified by means of said method, which can differentiate between SSc and other autoimmune diseases and between different SSc sub-groups. The invention also relates to panels, diagnostic means, and test kits which comprise said markers and to the use and application thereof, for example for the diagnosis, prognosis, and therapy control for SSc. The invention further relates to methods for screening and validating active ingredients for use in SSc sub-groups.
Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine antibodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.